Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Nephritis | 5 | 2024 | 42 | 1.260 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2022 | 194 | 0.560 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 9 | 0.500 |
Why?
|
| Basement Membrane | 1 | 2015 | 48 | 0.480 |
Why?
|
| Autoantibodies | 1 | 2015 | 435 | 0.380 |
Why?
|
| Biomarkers | 2 | 2024 | 3154 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 515 | 0.360 |
Why?
|
| Renal Dialysis | 1 | 2015 | 862 | 0.300 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 414 | 0.240 |
Why?
|
| Microscopic Polyangiitis | 1 | 2024 | 14 | 0.240 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2024 | 21 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 890 | 0.230 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2024 | 38 | 0.230 |
Why?
|
| Rituximab | 1 | 2024 | 157 | 0.220 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 653 | 0.210 |
Why?
|
| Remission Induction | 4 | 2024 | 297 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 513 | 0.180 |
Why?
|
| Antibodies, Antinuclear | 2 | 2024 | 28 | 0.180 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2018 | 77 | 0.150 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 52 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 731 | 0.140 |
Why?
|
| Kidney | 4 | 2024 | 1361 | 0.130 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 16 | 0.120 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 43 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 217 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 208 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 741 | 0.110 |
Why?
|
| Adolescent | 6 | 2024 | 19531 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 829 | 0.100 |
Why?
|
| Child | 7 | 2024 | 24739 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 784 | 0.100 |
Why?
|
| DNA | 1 | 2015 | 1623 | 0.080 |
Why?
|
| Female | 7 | 2024 | 67337 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3343 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4465 | 0.060 |
Why?
|
| Male | 6 | 2024 | 62042 | 0.060 |
Why?
|
| Humans | 8 | 2024 | 126366 | 0.060 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 44 | 0.060 |
Why?
|
| Complement C4 | 1 | 2024 | 5 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4468 | 0.060 |
Why?
|
| Blood Sedimentation | 1 | 2024 | 30 | 0.060 |
Why?
|
| Complement C3 | 1 | 2024 | 49 | 0.060 |
Why?
|
| Proteinuria | 1 | 2024 | 105 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 49 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 609 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2024 | 14207 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12386 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 16522 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 12667 | 0.040 |
Why?
|
| Biopsy | 1 | 2022 | 1257 | 0.040 |
Why?
|
| Mice | 1 | 2015 | 17877 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1453 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 4875 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1397 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 34548 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 6177 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 9166 | 0.010 |
Why?
|